At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 15, 2026 at 23:00 ET
HUTCHMED announced that three of its drugs (ELUNATE, ORPATHYS, SULANDA) will continue to be included in China's National Reimbursement Drug List (NRDL) effective January 1, 2027, with expanded coverage for new indications. This renewal supports ongoing commercial access and revenue from these products in China.
- ELUNATE (fruquintinib) newly included for renal cell carcinoma in combination with sintilimab
- ORPATHYS (savolitinib) newly included for EGFR-mutant NSCLC with MET amplification, in combination with osimertinib
- ORPATHYS renewed for NSCLC with MET exon 14 skipping alteration
- All previously included indications for ELUNATE, ORPATHYS and SULANDA maintained under multi-year agreements
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access